Fly News Breaks for May 28, 2019
May 28, 2019 | 07:44 EDT
After traveling with management, Cantor Fitzgerald analyst Alethia Young says PTC Therapeutics remains a top small-mid-cap franchise pick. The company has "many realizable shots on goal" that remain unappreciated at current share levels, Young tells investors in a research note. She thinks investors assign little credit to PTC's AADC deficiency opportunity in gene therapy. Young models peak sales of $400M and a 20% probability of success. The analyst reiterates an Overweight rating on PTC Therapeutics with a $61 price target.
News For PTCT From the Last 2 Days
Sep 17, 2019 | 18:54 EDT
HIGHER: NewLink (NLNK) up 17.8% after FDA accepted its partnered BLA for ebola vaccine... CDW Corp (CDW) up 5.6% after entering S&P500 index... Tellurian (TELL) up 2.0% after being initiated with Outperform at Evercore... NextDecade (NEXT) up 1.9% after being initiated with Outperform at Evercore. DOWN AFTER EARNINGS: FedEx (FDX) down 9.6%, XPO Logistics (XPO) down 3.4% in symbathy... Chewy (CHWY) down 2.8%... Adobe (ADBE) down 2.6%. ALSO LOWER: Adesto Technologies (IOTS) down 8.5% after convertible debt offering... PTC Therapeutics (PTCT) down 7.7% after equity offering... Translate Bio (TBIO) down 7.6%... Acadia Pharma (ACAD) down 2.6% after equity offering. Movers as of 18:30ET.
Sep 17, 2019 | 06:29 EDT
Citi analyst Joel Beatty removed The Medicines Co. (MDCO) and Minerva (NERV) from his top five Buy-rated stocks in SMid cap Biotech. These stocks are up 34% and 28%, respectively, since the analyst established them as among his top five Buy-rated stocks in July. Beatty replaced The Medicines Co. and Minerva with Amarin (AMRN) and Sarepta Therapeutics (SRPT). His top five buys are now Amarin, Eloxx Pharmaceuticals (ELOX), NGM Biopharmaceuticals (NGM), PTC Therapeutics (PTCT) and Sarepta. He wants to own Amarin into the November FDA panelmeeting, believing it will be "innocuous" and lead to a risk reduction label for Vascepa. On Sarepta, Beatty thinks the recent share pullback is overblown, and he reiterates his thesis that "although there will likely be some minor bumps on the road," the company will ultimately win the Image result for Duchenne muscular dystrophy gene therapy race